Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Content archived on 2024-06-18

OPTICAL BIOPSY PEN: A COMPACT AND LOW-COST DIAGNOSTIC TOOL FOR DERMATOLOGY BASED ON HIGH-PERFORMING INTEGRATED OCT

Project description


Heterogeneous Integration and take-up of of Key Enabling Technologies for Components and Systems

Optical coherence tomography (OCT) is an emerging optical diagnosis that enables in vivo tomographic visualization for non-invasive optical biopsy. OCT has proven its value primarily in ophthalmology, but recently also in dermatology. However, wide adoption has not taken place due to size and cost limitations as well as non-existence of handheld devices.Hence BIOPSYPEN will develop a new OCT generation with step-changes in size and cost beyond state-of-the-art to radically transform OCT instrumentation for handheld point-of-care diagnosis. In contrast to conventional approaches, BIOPSYPEN's OCT is based on integrated optics, more precisely on hybrid integration of silicon photonics with III-V sources, enabling a significantly smaller, low-cost, compact and maintenance free alternative.BIOPSYPEN will target complementary research to develop an unprecedented compact (pencil-like), reliable, low-cost, battery-operated, wireless handheld OCT device in combination with an embedded system based external console to receive two-and three-dimensional tomograms for instantaneous post processing and visualization as well as immediate diagnosis.BIOPSYPEN will contribute to a significantly wider adoption of OCT in real clinical point of care settings. Early diagnosis of skin cancer and inflammatory skin diseases are envisaged. Skin cancer will be used as a surrogate for other epithelial cancers, e.g. oral, gynaecologic or gastrointestinal cancer. Partnerships with leading innovative clinical users will enable preclinical evaluation.Through the use of integrated optics in combination with complementary cutting-edge technologies, BIOPSYPEN will dramatically reduce cost and size (both at least by one order of magnitude) of currently available OCT commercial systems. It will also eliminate instrumentation maintenance requirements and will reduce training and healthcare costs, paving the way to revolutionize diagnosis for general medicine and primary care.

Call for proposal

FP7-ICT-2013-10
See other projects for this call

Coordinator

MEDLUMICS SL
EU contribution
€ 601 838,00
Address
PLAZA DE LA ENCINA 10-11, NUM. 10 NUCLEO 3-2-A
28760 Tres Cantos Madrid
Spain

See on map

Region
Comunidad de Madrid Comunidad de Madrid Madrid
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Jose Luis Rubio (Mr.)
Links
Total cost
No data

Participants (8)